Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    2,711

Stocks News & Analysis

stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks

Chart of the Week: US equity market trading at an attractive discount

The latest from our Chief US Market Strategist.
stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.9043.800.48%
CAC 408,245.8018.07-0.22%
DAX 4023,806.99273.64-1.14%
Dow JONES (US)48,301.90391.980.82%
FTSE 10010,603.485.40-0.05%
HKSE25,752.40140.62-0.54%
NASDAQ22,810.76175.760.78%
Nikkei 22555,895.32413.10-0.73%
NZX 50 Index13,273.8119.870.15%
S&P 5006,829.5246.710.69%
S&P/ASX 2008,973.2057.800.65%
SSE Composite Index3,966.1728.83-0.72%

Market Movers